Stocks / NASDAQ / MBX Biosciences Inc.

MBX Biosciences Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: MBX – NASDAQ

Animal Usage: Animal Testing

Our Opinion

MBX Biosciences Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in the following report that they exploit animals for product testing.

“Failure to access or a significant delay in accessing animal research models may materially adversely affect our ability to advance our preclinical programs and successfully develop any product candidates, which could result in significant harm to our business.” (Page 47) Read the full document

Company Description

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. The company was founded in 2018 and is based in Carmel, Indiana.

Company Website: https://www.mbxbio.com

Contact: info@mbxbio.com